Applications
Detox & Cleanse Product Development Solutions
Mechanism-led R&D, formulation and pilot manufacturing for products that support the body’s endogenous biotransformation, conjugation and elimination pathways — engineered for analytical reproducibility, toxicological defensibility and market-specific claim compliance.
Applications
End-to-End Turnkey Solutions for Detox & Cleanse Product Development
Detoxification is not a marketing opportunity. It is a specific set of enzymatic and membrane-transport mechanisms through which metabolism and xenobiotic products are functionalized, conjugated and removed. Such a product must be formulated with respect to a specific node within this process, its action on that node must be measurable, and the language of such an action has to be approved in the market in which that product will be marketed.
Food Research Lab designs detox product research and development solutions for manufacturers, contract packers and start-ups in the food, functional food, beverages, nutraceuticals and cosmeceuticals sectors. From the consumer concept or ingredient hypothesis to a validated and scalable dossier — and while doing that, we also design the claim pathway alongside the formula development, not afterwards.
What a turnkey engagement covers
- Definition of concept, mechanism of action pathway, competitive white space analysis and claim feasibility assessment for each target market
- Selection of ingredients with mechanism of action explanation, dose validation and ingredient regulatory status verification in all target markets
- Bench formulation, prototyping and sensory refinement
- Analytical method development, analyte quantification and specifications definition
- Conduct of stability studies according to ICH Q1A(R2), including exposure of the formulations to Climatic Zone IVb conditions.
- Toxicological risk assessment, contaminant control strategy and creation of safety dossiers
- Pilot manufacturing, critical process parameter determination and technology transfer to your facility or a contracted manufacturer
- Claim substantiation strategy and regulatory filing documentation preparation for each target market
- Supply chain management and procurement of standardised, traceable ingredients
The Science We Formulate Against: Phase I, II and III Biotransformation
- Phase I — functionalisation. In the cytochrome P450 isoenzymes (mainly CYP1A1, CYP1A2, CYP1B1, CYP2E1 and CYP3A4), the reactive functional groups are introduced by the processes of oxidation, reduction, and hydrolysis. The intermediates created are often more reactive than the parent molecules. [1]
- Phase II — conjugation. In the UDP-glucuronosyltransferases (UGT), sulfotransferases (SULT), glutathione S-transferases (GST), N-acetyltransferases (NAT1/NAT2) and catechol-O-methyltransferase (COMT), the intermediates are conjugated with glucuronic acid, sulfate, glutathione, acetyl and methyl groups, making them more hydrophilic and ready to be excreted. [1]
- Phase III — efflux and elimination. ATP-binding cassette transporters — MRP2 (ABCC2), P-glycoprotein (ABCB1) and BCRP (ABCG2) — export conjugates into bile and urine [1]. Clearance then depends on hepatobiliary secretion, glomerular filtration and tubular secretion, colonic transit and, to a lesser degree, pulmonary and eccrine routes.
The design principle most detox formulations get wrong
Inducing Phase I without matched Phase II and Phase III capacity increases the systemic burden of reactive electrophilic intermediates rather than reducing it. Uncoupled induction is a formulation defect, not a benefit.
Thus, FRL targets balanced pathway capacities: conjugation and efflux capacities are determined first, and any Phase I modulator will be dosed in relation to this ceiling. The same rationale determines our position in relation to absorption enhancers – see Bioavailability Engineering.
| Application area | Mechanistic target | Representative actives | Claim architecture |
| Hepatic support | Conjugation capacity, glutathione status, bile flow, Nrf2–ARE battery | Silybin-phosphatidylcholine, choline, betaine, artichoke, sulforaphane precursors | EU: choline liver-function claim at claim-bearing dose. Canada: NNHPD monograph wording. Korea: notified milk thistle route. China: auxiliary protection against chemical liver injury. |
| Intestinal elimination | Transit time, faecal bulk, SCFA production, β-glucuronidase modulation | Psyllium, chicory inulin, wheat bran fibre, FOS/GOS, PHGG, defined probiotic strains | EU: wheat bran fibre transit and faecal bulk claims; chicory inulin bowel-function claim. Intakes are high and drive format choice. China: intestinal transit function. |
| Dermal and nutricosmetic | Dermal antioxidant capacity, collagen substrate supply, microcirculation | Collagen peptides, vitamin C, carotenoids, tocopherols, polyphenol fractions | EU: vitamin C collagen-formation claim; biotin, niacin and zinc skin-maintenance claims. Category determination first — ingestible, topical or both. |
| Endocrine metabolite clearance | CYP1A1/1B1 hydroxylation balance, COMT methylation, glucuronidation | I3C/DIM, calcium-D-glucarate, sulforaphane precursors, B-vitamin cofactors | Highest claim risk in the category. EU: folate, B12 and magnesium cofactor claims only. Never name a clinical condition in any market. |
| Immune and inflammatory tone | Normal inflammatory signalling, antioxidant reserve, barrier integrity | Vitamin C, vitamin D, zinc, selenium, long-chain omega-3, polyphenols | EU: vitamin and mineral immune-function claims are the compliant backbone. Botanical claims are unavailable. |
| Energy and bioenergetics | Electron transport efficiency, fatty-acid transport, NAD⁺ availability, PGC-1α | CoQ10/ubiquinol, ALA, carnitines, riboflavin, magnesium, B-complex | EU: energy-yielding metabolism and reduction-of-tiredness claims across riboflavin, niacin, B6, B12, vitamin C, magnesium, iron and pantothenic acid. |
| Hydration-led beverage formats | Fluid balance supporting renal clearance | Electrolyte systems, low-osmolality carbohydrate, botanical flavour fractions | EU: the authorised water claims apply at 2 L/day from all sources and carry strict conditions of use — usable in campaign context, not as a product-specific claim. |
FRL selects detox and cleanse ingredients based on scientific evidence, standardization, safety, analytical control, and regulatory suitability.
Liver-Supportive Botanicals
- Milk Thistle (Silymarin) – Hepatoprotective and antioxidant
Antioxidants & Glutathione Precursors
- NAC, alpha-lipoic acid, vitamins C and E, selenium, resveratrol, and quercetin.
Gut & Elimination Support
- Psyllium, PHGG, inulin, FOS, GOS, resistant starch, probiotics, and digestive enzymes.
Targeted Functional Ingredients
- Selected ingredients are evaluated for formulation compatibility, bioavailability, stability, safety, and market-specific regulatory requirements.
Restricted & High-Scrutiny Ingredients
FRL screens high-scrutiny ingredients at the concept stage to identify safety, regulatory, claim, and market-access risks before formulation development. Where appropriate, alternative ingredients and reformulation strategies are evaluated.
FRL applies a science-driven validation framework to ensure detox and cleanse formulations are safe, effective, stable, and commercially scalable. Our approach integrates toxicological assessment, contaminant screening, analytical validation, stability testing, ingredient standardization, and regulatory requirements.
- Safety & Regulatory Validation:
Safety assessment includes toxicological review, herb–drug interaction assessment, microbiological testing, heavy metal and contaminant screening, allergen evaluation, and risk assessment for sensitive populations. - Analytical & Stability Assurance:
FRL evaluates ingredient identity, purity, potency, marker compounds, microbiological quality, physical properties, shelf life, and packaging compatibility using appropriate analytical and stability protocols.
FRL integrates Detox product regulatory support into formulation development from the outset, aligning ingredients, dosage, product formats, labeling, and claims with applicable market requirements. Since “detox” and “cleanse” are not themselves universally authorised health claims, formulations are designed around permitted claim pathways and scientifically substantiated benefits.
Regulatory Framework Alignment
FRL supports detox and cleanse product development across major markets, including:
- USA: FDA, DSHEA and cGMP requirements
- European Union: EFSA health-claim and Novel Food requirements
- India: FSSAI nutraceutical and food regulations
- Japan: MHLW, FOSHU and FFC frameworks
- China: Applicable health-food and ingredient requirements
- Australia & New Zealand: TGA and FSANZ requirements
Regulatory Documentation & Compliance Support
FRL supports ingredient verification, specification review, safety and contaminant assessment, stability studies, label compliance, claim substantiation, technical documentation, and global regulatory readiness for scalable detox and cleanse products.
Explore Detox Claim Mapping & Global Regulatory Requirements →
Therapeutic Positioning & Target-Specific Detox & Cleanse Product Architecture
FRL formulates against six primary physiological targets, built on mechanism rather than clinical outcome detox itself is not an authorised claim in any major market.
The liver is the principal site of detoxification, clearing compounds through a three-phase process: activation, conjugation and export. FRL formulations target substrate supply for glutathione synthesis, activation of the body’s own antioxidant response pathway, and healthy bile flow.
The gut is the primary elimination route for detoxification by-products. Formulation targets include healthy transit time, short-chain fatty acid production from fibre fermentation, and gut barrier integrity.
Skin condition reflects systemic oxidative load. FRL develops both ingestible and topical routes, with product category — cosmetic or supplement — confirmed at the outset, since classification and permitted claims differ by market.
Detoxification is also closely associated with hormonal balance and particularly with estrogen metabolism. Impaired detoxification could play a role in estrogen dominance, PMS, erratic menstrual cycles, and weight gain secondary to a slowed metabolism.
FRL develops targeted cleanse supplement formulation systems that:
- Support estrogen conjugation and clearance
- Promote liver-mediated hormone balance
- Reduce inflammatory burden linked to hormonal fluctuations
- Support thyroid-metabolic synergy
These solutions are also relevant to women dealing with PMS or perimenopause and hormonal weight retention.
Reducing oxidative and toxin load supports normal immune signalling rather than suppressing a disease process, and formulations here are built accordingly.
Detoxification and cellular energy metabolism share the same enzymatic machinery. FRL targets electron-carrier sufficiency and mitochondrial antioxidant defence.
Product Formats & Delivery Systems – Pilot Manufacturing & Commercial Scale Solutions
| Format | Process technology | Critical quality attributes | Typical application |
| Hard capsules (HPMC / gelatin) | Blending, roller compaction or dry granulation, encapsulation; delayed-release coating with HPMCP, shellac or methacrylate polymers | Blend uniformity, fill-weight RSD, Carr’s index and Hausner ratio, disintegration to USP <2040> | Standardised botanicals, hepatic support, endocrine metabolite clearance |
| Softgels | Lipid-matrix preparation, rotary-die encapsulation, shell plasticiser balance | Fill homogeneity, shell moisture, seam integrity, cross-linking risk on ageing | Lipophilic actives — CoQ10, tocopherols, phytosterols, phospholipid complexes |
| Tablets | Wet or dry granulation, direct compression, film coating | Hardness, friability, disintegration, content uniformity, punch-sticking control for hygroscopic botanicals | Multi-actives with sufficient dose and compressibility |
| Powder sachets and stick packs | Dry blending, agglomeration, fluid-bed granulation, spray drying | Bulk and tapped density, flow, dispersibility, water activity, segregation control | Fibre systems at claim-bearing intake, greens blends, meal-replacement bases |
| RTD beverages and shots | Hot fill, aseptic fill or HPP; pH and hurdle design; homogenisation | pH, Brix, turbidity, sedimentation, colour drift, active retention through thermal load, package permeability | Detox functional beverage R&D, hydration and antioxidant formats |
| Herbal infusions | Cut-size and particle-size grading, blending, extraction-yield modelling | Extraction yield, marker delivery per infusion, microbial load of dried botanicals, PAH control | Gentle daily-use cleanse positioning |
| Gummies and pastilles | Pectin or gelatin depositing, starch mogul or starchless, sugar-reduced systems | Water activity, texture stability, active recovery after depositing heat, sugar-alcohol tolerance load | Consumer-friendly daily formats |
| Liquid tonics and syrups | Extraction, blending, preservation system design, filtration | Microbial stability, phase separation, active degradation, taste stability of bitter fractions | Choleretic and digestive positioning |
| Functional foods and bars | Extrusion, cold-press forming, coating | Water-activity migration between phases, hardening on storage, active survival through extrusion | Long-term metabolic and fibre programmes |
Development Workflow — Stage-Gated Execution
Each stage closes with a defined deliverable and a go/no-go decision. Claim feasibility and regulatory screening sit at Stage 1, not Stage 5.| Stage | Activity | Deliverable | Gate criterion |
| 1. Concept and pathway mapping | Target consumer definition, positioning, pathway node selection, market shortlist, authorised-claim mapping and dose implications | Concept brief with mechanistic rationale, claim map and format constraints per market | A permitted claim route exists in every priority market and its dose requirement is compatible with the intended format |
| 2. Ingredient architecture | Active selection, dose justification from published human data, regulatory status screening, supplier qualification | Ingredient dossier with status flags, supplier COAs and cost model | No ingredient carries an unresolved prohibition, novel-food gap or scrutiny flag in a priority market |
| 3. Formulation and prototyping | Bench formulation, excipient compatibility, delivery-system selection, sensory optimisation, iterative prototyping | Prototype with draft specification and pilot process outline | Prototype meets target profile, carries the claim-bearing nutrient dose, and is viable at target cost of goods |
| 4. Validation | Analytical method development and validation, contaminant and microbiological testing, stability initiation, toxicological assessment, substantiation studies where required | Validated specification, stability protocol, safety and substantiation file | Claim-critical specifications are achievable at scale and the safety file is complete |
| 5. Scale-up and launch | Pilot manufacturing, CPP definition, process validation batches, packaging qualification, dossier submission, technology transfer | Batch manufacturing record, validation report, market-ready regulatory dossier | Three consecutive conforming validation batches and dossier accepted |
Segments Served
- Food and functional food — fibre-enriched and fortified formats, bars, meal replacements, culinary systems
- Beverages — RTD functional drinks, shots, powder-to-water systems, infusions; detox functional beverage R&D from bench through hot-fill, aseptic and HPP pilot runs
- Nutraceuticals — capsules, tablets, softgels, sachets, gummies and liquid formats
- Cosmeceuticals and nutricosmetics — ingestible beauty systems and topical formulations, with category determination and cosmetic-regulation compliance handled as part of scope
- Client profile — established manufacturers extending into functional wellness, contract manufacturers building a house portfolio, and funded startups needing a full technical and regulatory package to reach first production
Why Choose FRL
- Mechanism-led formulation. Products are designed against named pathway nodes with measurable endpoints, not against category trends.
- Claim-backwards design. We map the authorised wording in each target market before bench work begins, and set the dose at the level that wording requires. This is where detox launches are usually lost.
- Regulatory screening at concept stage. Ingredient status is resolved before formulation, which is where reformulation cost is actually avoided.
- Current case law, not last decade’s assumptions. The botanical claims position changed in April 2025 and the hydroxyanthracene position is live. We track them and date our positions.
- Analytical depth. Method development, marker validation, contaminant panels and ICH-compliant stability, including Zone IVb conditions for South Asian and ASEAN markets.
- Delivery technology without mechanistic compromise. Phospholipid complexation, self-emulsifying systems, cyclodextrin complexation, amorphous dispersions and encapsulation — selected against the product’s own pathway logic.
- Pilot manufacturing and transferable process definition. Scale-up with defined critical process parameters and documentation your contract manufacturer can execute against.
- Sourcing and procurement. Standardised, traceable, audited raw materials with identity confirmation.
- One accountable partner from concept through validation batches and dossier submission.
Frequently Asked Questions
No, not as a health claim. Detox, cleanse and similar wordings are not on the EU Register of authorised health claims, and Article 10(1) of Regulation (EC) 1924/2006 prohibits health claims that are not authorised. Detox can function as brand and category language, but the substantive on-pack claim must come from authorised wording — for example a choline liver-function claim or an authorised fibre and bowel-function claim.
Generally no. The Court of Justice confirmed in April 2025 (Case C-386/23, Novel Nutriology) that botanical health claims cannot be used without authorisation, despite the long-running suspension of the Commission’s botanical claim evaluation. The transitional route survives only where the claim was applied for before 19 January 2008 and remains on the on-hold list. In practice the claim on a botanical-led formula must be attributed to a nutrient in the formula.
Twelve grams of native chicory inulin per day. The claim is ingredient-specific and dose-specific, the consumer must be informed of the 12 g intake, and the 12 g may be divided across servings. This requirement usually rules out capsule formats and drives the product toward a sachet, powder or food carrier.
The position is unsettled. Commission Regulation (EU) 2021/468 restricted senna and related hydroxyanthracene-bearing botanicals. The EU General Court annulled the substantive provisions in November 2024, but the Commission has appealed and that appeal suspends the annulment, so the restriction remains operative pending judgment. Anyone planning an EU cleanse launch on a cathartic anthraquinone base should treat the ingredient as high risk in either direction.
In the United States, NAC is excluded from the dietary supplement definition because it was approved as a drug before being marketed as a supplement. FDA finalised an enforcement-discretion policy in August 2022 and products remain on sale under it, but that is discretion rather than entitlement. In several EU member states NAC is regulated as a medicinal product. A contingency reformulation should be documented in advance.
A daily portion must contain less than 800 mg EGCG. The label must declare EGCG content per portion and the maximum number of daily portions, and must carry warnings covering the daily cap, concurrent green tea products, pregnancy, lactation and under-18s, and consumption on an empty stomach. Traditionally prepared infusions are outside the scope of the restriction.
Canada and South Korea are the most accessible. Health Canada’s NNHPD publishes monographs that pre-clear specific ingredients, doses and claim wordings, and monograph-compliant submissions receive the fastest review class. In South Korea, milk thistle extract is a notified functional ingredient for liver health at a defined silymarin intake, which avoids individual approval. Designing to either specification from the outset removes months from the timeline.
Phase I is functionalisation — cytochrome P450 enzymes oxidise, reduce or hydrolyse a compound to expose a reactive group. Phase II is conjugation — enzyme families including UGT, SULT, GST and COMT attach glucuronic acid, sulfate, glutathione or a methyl group, making the metabolite water-soluble. Phase III is efflux, where transporters export the conjugate into bile or urine. The practical point for formulation is that stimulating Phase I without matching Phase II and III capacity increases reactive intermediate load rather than reducing it.
It depends on the claim and the market. A US structure/function claim requires competent and reliable scientific evidence, which FTC guidance interprets as human randomised trials in most cases. An EU authorised claim requires only that the product meets the published conditions of use — no new trial is needed, which is precisely why claim mapping is cost-efficient. A new proprietary claim, an Article 13(5) application or a China health food registration each require original human data.
For a formulation built on established ingredients and existing authorised claims, typically six to nine months from brief to validation batches, with stability running in parallel. Ingredients requiring novel food authorisation, NDI notification or China health food registration add years rather than months — which is why regulatory screening sits at stage one of our workflow rather than at the end.
Let’s create something Innovative and Delicious together
Food Research Lab strives for excellence in new Food, Beverage and Nutraceutical Product Research and Development by offering cutting edge scientific analysis and expertise.
